Gout Therapeutics Market Report 2026

The gout therapeutics market size has grown rapidly in recent years. It will grow from $3.22 billion in 2025 to $3.59 billion in 2026 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to dietary lifestyle changes, NSAID availability, increased arthritis diagnosis, hospital rheumatology services, pain management drug development.

The gout therapeutics market size is expected to see rapid growth in the next few years. It will grow to $5.6 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to aging population growth, chronic disease burden, preventive arthritis care, improved patient compliance tools, personalized treatment approaches. Major trends in the forecast period include rising prevalence of lifestyle-related arthritis, increased use of uric acid lowering therapies, expansion of chronic gout management, growing awareness of early diagnosis, improved long-term disease monitoring.

The rising prevalence of gout is expected to drive the growth of the gout therapeutics market in the coming years. Gout is an inflammatory arthritis condition that causes joint pain and swelling. Its increasing occurrence is largely attributed to obesity and metabolic syndrome, which elevate uric acid levels in the blood, leading to the formation of urate crystals in joints. Gout therapeutics work by lowering uric acid levels, managing inflammation, and preventing flare-ups to reduce the frequency and severity of the condition. For example, in June 2025, PubMed Central, a US-based biomedical and life sciences platform, reported that by 2050, age-standardized incidence and prevalence rates of gout are projected to rise further, highlighting the growing global burden of the disease. Additionally, according to the National Library of Medicine in June 2024, the prevalence of comorbid gout and chronic kidney disease (CKD) in the USA was 7.9 million in 2023, expected to increase by 29% to 9.6 million by 2035 under the baseline scenario. Therefore, the rising incidence of gout is driving the growth of the gout therapeutics market.

Major companies in the gout therapeutics market are developing innovative treatments, such as urate transporter inhibitors, which regulate the reabsorption of uric acid from urine back into the blood. Urate transporters are proteins that move uric acid across cell membranes in the kidneys or intestines to maintain healthy blood uric acid levels. For instance, in July 2025, Eisai Co. Ltd., a Japan-based pharmaceutical company, launched URECE (dotinurad), a selective urate transporter 1 (URAT1) inhibitor, as part of its global specialty care portfolio. URECE treats hyperuricemia associated with gout by increasing renal excretion of uric acid, lowering serum uric acid levels. It also demonstrates a favorable safety profile with minimal off-target effects and is effective in patients with mild-to-moderate renal impairment, making it suitable for a wide range of gout patients.

In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. Through this acquisition, Amgen aimed to strengthen and expand its rare-disease and inflammation drug portfolio, broadening its therapeutic offerings and accelerating revenue growth. Horizon Therapeutics plc is an Ireland-based biopharmaceutical company specializing in gout therapeutics.

Major companies operating in the gout therapeutics market are Takeda Pharmaceutical Company Ltd, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, Teijin Pharma Ltd, Zydus Group, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddy’s Laboratories Ltd, Amneal Pharmaceuticals Inc, Lupin Limited, Ironwood Pharmaceuticals Inc, Pharvaris NV, Selecta Biosciences Inc, Dyve Biosciences Inc, Arthrosi Therapeutics Inc, Atom Therapeutics Co Ltd, Olatec Therapeutics LLC.

North America was the largest region in the gout therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gout therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gout therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gout therapeutics market by increasing costs of imported anti-inflammatory drugs, uric acid inhibitors, and pharmaceutical ingredients. Hospitals and specialty clinics are most affected due to reliance on imported medications. These tariffs raise treatment costs by increasing expenses for chronic urate-lowering therapy and acute flare management, affecting long-term disease control. However, they encourage domestic drug production, supporting local manufacturing of gout medications and key active ingredients.

The gout therapeutics market research report is one of a series of new reports that provides gout therapeutics market statistics, including gout therapeutics industry global market size, regional shares, competitors with a gout therapeutics market share, detailed gout therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the gout therapeutics industry. This gout therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gout therapeutics refer to medications used to treat gout, a form of inflammatory arthritis that causes pain and swelling in the joints. These therapeutics help relieve joint pain, swelling, and tenderness.

The main types of gout therapeutics include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and diuretics. NSAIDs are medications used to reduce inflammation, relieve pain, and lower fever. Treatments also include xanthine oxidase inhibitors and uricosuric medications, which are used for managing both acute and chronic gout conditions. These therapies are utilized by various end users, including hospitals, specialty clinics, and others.

The gout therapeutics market consists of the sales of allopurinol, benzbromarone, febuxostat, probenecid, and pegloticase drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.